Randomized Evaluation of Shenfu Injection to Reduce Myocardial Injury
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
This study aims to evaluate whether perioperative use of Shenfu Injection, as compared to
placebo, could reduce infarct size assessed by cardiac magnetic resonance (CMR) in patients
with acute anterior ST-segment elevation myocardial infarction (STEMI) undergoing primary
percutaneous coronary intervention (PCI).